This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Travelers' Diarrhea (TD) Vaccine Patch
Description: Iomai's Traveler's Diarrhea Vaccine is a skin patch based on Iomai's novel transcutaneous immunization (TCI) technology. The patch works by delivering vaccine to a group of antigen-presenting cells in the skin called Langerhans cells, which transport the vaccine to nearby lymph nodes to produce a sustained immune response. Enterotoxigenic E. coli (ETEC) bacteria causes illness through the toxins it produces, including one known as heat-labile toxin or LT. Iomai's patch-based vaccine enables the safe administration of this immunogen into the skin to stimulate the immune response.
Deal Structure: In August 2008, Intercell AG announced the completion of the acquisition of Iomai.
In December 2009, Intercell and GlaxoSmithKline Biologicals (GSK) announced an agreement to form a strategic alliance to accelerate the development and commercialization of needle-free, patch-based vaccines. The agreement will include Intercell's candidate vaccine for travelers' diarrhea (TD) and an investigational single application pandemic influenza vaccine, as well as the use of the patch technology for other vaccines in GSK's portfolio.
Under the terms of the agreement, GSK will make an up-front cash contribution of EUR 33.6 (USD 49.4) million, in addition to an equity investment of up to EUR 84 (USD 123.5) million through a staggered shareholding purchase option of up to 5 % in Intercell.
In May 2013, Valneva announced its creation through the completion of the merger of equals between Vivalis and Intercell.
Partners: GlaxoSmithKline plc
ETEC Vaccine News
Additional information available to subscribers only: